274 related articles for article (PubMed ID: 18199095)
21. Beneficial hematologic effects of daily oral ascorbic acid therapy in ESRD patients with anemia and abnormal iron homeostasis: a preliminary study.
Sirover WD; Siddiqui AA; Benz RL
Ren Fail; 2008; 30(9):884-9. PubMed ID: 18925528
[TBL] [Abstract][Full Text] [Related]
22. Effects of carnitine supplementation on muscle metabolism by the use of magnetic resonance spectroscopy and near-infrared spectroscopy in end-stage renal disease.
Vaux EC; Taylor DJ; Altmann P; Rajagopalan B; Graham K; Cooper R; Bonomo Y; Styles P
Nephron Clin Pract; 2004; 97(2):c41-8. PubMed ID: 15218329
[TBL] [Abstract][Full Text] [Related]
23. Erythropoietin-resistant refractory renal anemia: effects of oral L-carnitine supplementation.
Kawabata M; Kasuga S; Hara H; Suyama S; Moriyama K; Takabatake T
Clin Nephrol; 2001 Mar; 55(3):265-6. PubMed ID: 11316253
[No Abstract] [Full Text] [Related]
24. The effects of L-carnitine on respiratory function tests in children undergoing chronic hemodialysis.
Kavukçu S; Türkmen M; Salman S; Onvural B; Oktay G; Karaman O; Cevik NT
Turk J Pediatr; 1998; 40(1):79-84. PubMed ID: 9673532
[TBL] [Abstract][Full Text] [Related]
25. L-Carnitine in the treatment of fatigue in adult celiac disease patients: a pilot study.
Ciacci C; Peluso G; Iannoni E; Siniscalchi M; Iovino P; Rispo A; Tortora R; Bucci C; Zingone F; Margarucci S; Calvani M
Dig Liver Dis; 2007 Oct; 39(10):922-8. PubMed ID: 17693145
[TBL] [Abstract][Full Text] [Related]
26. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
27. How can erythropoietin requirements be reduced in dialysis patients?
Kotanko P; Levin NW; Fishbane S; Tarng DC; Berns JS
Semin Dial; 2006; 19(5):363-72. PubMed ID: 16970733
[No Abstract] [Full Text] [Related]
28. A pharmacokinetic model for L-carnitine in patients receiving haemodialysis.
Fornasini G; Upton RN; Evans AM
Br J Clin Pharmacol; 2007 Sep; 64(3):335-45. PubMed ID: 17506778
[TBL] [Abstract][Full Text] [Related]
29. Short-term effects of nocturnal haemodialysis on carnitine metabolism.
Hothi DK; Geary DF; Fisher L; Chan CT
Nephrol Dial Transplant; 2006 Sep; 21(9):2637-41. PubMed ID: 16822785
[TBL] [Abstract][Full Text] [Related]
30. Homocysteine as a risk factor for cardiovascular disease in patients treated by dialysis: a meta-analysis.
Heinz J; Kropf S; Luley C; Dierkes J
Am J Kidney Dis; 2009 Sep; 54(3):478-89. PubMed ID: 19359080
[TBL] [Abstract][Full Text] [Related]
31. L-carnitine in dialysed patients: the choice of dosage regimen.
Berard E; Iordache A; Barrillon D; Bayle J
Int J Clin Pharmacol Res; 1995; 15(3):127-33. PubMed ID: 8847154
[TBL] [Abstract][Full Text] [Related]
32. Effects of monthly dose and regular dosing of intravenous active vitamin D use on mortality among patients undergoing hemodialysis.
St Peter WL; Li S; Liu J; Gilbertson DT; Arneson TJ; Collins AJ
Pharmacotherapy; 2009 Feb; 29(2):154-64. PubMed ID: 19170585
[TBL] [Abstract][Full Text] [Related]
33. Debate forum: carnitine supplements have not been demonstrated as effective in patients on long-term dialysis therapy.
Handelman GJ
Blood Purif; 2006; 24(1):140-2. PubMed ID: 16361854
[TBL] [Abstract][Full Text] [Related]
34. Effects of L-Carnitine supplement on plasma coagulation and anticoagulation factors in hemodialysis patients.
Hakeshzadeh F; Tabibi H; Ahmadinejad M; Malakoutian T; Hedayati M
Ren Fail; 2010; 32(9):1109-14. PubMed ID: 20863217
[TBL] [Abstract][Full Text] [Related]
35. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.
Wizemann V; Rutkowski B; Baldamus C; Scigalla P; Koytchev R;
Curr Med Res Opin; 2008 Mar; 24(3):625-37. PubMed ID: 18208642
[TBL] [Abstract][Full Text] [Related]
36. Oral L-carnitine does not decrease erythropoietin requirement in pediatric dialysis.
Lilien MR; Duran M; Quak JM; Frankhuisen JJ; Schröder CH
Pediatr Nephrol; 2000 Nov; 15(1-2):17-20. PubMed ID: 11095004
[TBL] [Abstract][Full Text] [Related]
37. Orally administrated Juzen-taiho-to/TJ-48 ameliorates erythropoietin (rHuEPO)-resistant anemia in patients on hemodialysis.
Nakamoto H; Mimura T; Honda N
Hemodial Int; 2008 Oct; 12 Suppl 2():S9-S14. PubMed ID: 18837771
[TBL] [Abstract][Full Text] [Related]
38. L-carnitine treatment of anemia.
Golper TA; Goral S; Becker BN; Langman CB
Am J Kidney Dis; 2003 Apr; 41(4 Suppl 4):S27-34. PubMed ID: 12751051
[TBL] [Abstract][Full Text] [Related]
39. L carnitine in hemodialysis patients.
Calò LA; Vertolli U; Davis PA; Savica V
Hemodial Int; 2012 Jul; 16(3):428-34. PubMed ID: 22360675
[TBL] [Abstract][Full Text] [Related]
40. Antimyopathic effects of carnitine and nicotine.
Laviano A; Meguid MM; Guijarro A; Muscaritoli M; Cascino A; Preziosa I; Molfino A; Rossi Fanelli F
Curr Opin Clin Nutr Metab Care; 2006 Jul; 9(4):442-8. PubMed ID: 16778574
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
